Physician profile
Shea Puttkammer
NPI 1619184835
$24,430.93
in general payments reported to CMS, 2019-2025
59 companies · $2,392 in 2025
The $2,392 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,685 · 2020: $3,119 · 2021: $5,411 · 2022: $3,486 · 2023: $2,143 · 2024: $2,193 · 2025: $2,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,728.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $5,901.06 | 2019-2023 | Januvia, Janumet, Steglatro |
| Dexcom, INC. | $5,882.82 | 2019-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $1,403.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,261.02 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $904.94 | 2019-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $750.36 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Insulet Corporation | $616.03 | 2019-2025 | Omnipod |
| Radius Health, INC. | $573.35 | 2020-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $561.01 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $551.55 | 2019-2025 | Unithroid |
| Antares Pharma, INC. | $532.89 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Xeris Pharmaceuticals, INC. | $422.15 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $356.78 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.81 | 2019-2025 | Jardiance, Tradjenta |
| Mannkind Corporation | $300.83 | 2020-2025 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $299.88 | 2022-2025 | |
| Esperion Therapeutics, INC. | $248.74 | 2020-2025 | Nexletol |
| Tolmar, INC. | $224.45 | 2023-2025 | Jatenzo |
| Alexion Pharmaceuticals, INC. | $208.48 | 2019-2025 | Strensiq |
| Abbvie INC. | $206.22 | 2019-2025 | Synthroid |
| Ibsa Pharma INC. | $197.14 | 2019-2025 | Licart, Tirosint, Flector |
| Cequr Corporation | $196.99 | 2023-2025 | Cequr Simplicity |
| Lifescan, INC. | $173.66 | 2019-2023 | |
| Shire North American Group INC | $157.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.78 | 2021-2025 | |
| Amarin Pharma, INC. | $149.33 | 2019-2022 | |
| Astellas Pharma US INC | $138.34 | 2024-2025 | Veozah |
| Tandem Diabetes Care, INC. | $131.67 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Enterra Medical, INC. | $121.14 | 2023 | |
| Ascendis Pharma Endocrinology INC | $119.53 | 2023-2025 | Yorvipath |
| Beta Bionics, INC. | $113.33 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Horizon Therapeutics Plc | $112.37 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $103.37 | 2021-2025 | Isturisa, Signifor Lar |
| Sequel Med Tech, LLC | $88.35 | 2025 | Twiist |
| Pfizer INC. | $86.08 | 2019-2023 | |
| Medtronic, INC. | $69.66 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Medtronic Minimed, INC. | $63.06 | 2019-2020 | |
| Clarus Therapeutics INC. | $59.51 | 2021 | |
| Neurocrine Biosciences, INC. | $57.67 | 2024-2025 | |
| Valeritas, INC. | $56.47 | 2019 | |
| Corcept Therapeutics | $48.03 | 2024 | Korlym |
| Verity Pharmaceuticals INC. | $43.26 | 2024 | Tlando |
| Nevro Corp. | $41.87 | 2023 | Senza |
| Kowa Pharmaceuticals America, INC. | $39.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.84 | 2019-2020 | |
| Rhythm Pharmaceuticals, INC. | $35.58 | 2025 | Imcivree |
| Inspire Medical Systems, INC. | $30.31 | 2024 | Inspire |
| Eusa Pharma (US) LLC | $29.20 | 2022 | |
| Zealand Pharma US, INC. | $26.27 | 2021-2022 | |
| Aytu Biopharma, INC. | $25.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.79 | 2020 | |
| Kyowa Kirin, INC. | $22.71 | 2023 | |
| Amag Pharmaceuticals, INC. | $20.14 | 2019 | |
| Metuchen Pharmaceuticals | $19.41 | 2019 | |
| Azurity Pharmaceuticals, INC. | $19.16 | 2025 | Azmiro |
| Becton, Dickinson and Company | $18.41 | 2019 | |
| Averitas Pharma INC. | $18.34 | 2025 | Qutenza |
| Currax Pharmaceuticals LLC | $13.66 | 2022 | |
| Halozyme INC | $12.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shea Puttkammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.